DTaP vaccine confers imperfect but long-term immunity

  • Domenech de Cellès M & al.
  • JAMA Pediatr
  • 22 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Diphtheria-tetanus-acellular pertussis (DTaP) vaccine confers imperfect but long-term immunologic protection.
  • Modeling demonstrates that temporal trends do not adequately capture pertussis acquisition odds; measures of vaccine effectiveness are incomplete.

Why this matters

  • DTaP vaccination is encouraged in all children per CDC guidance.
  • Despite occasional periodic pertussis outbreaks, DTaP confers indirect, herd immunity.

Key results

  • DTaP effectiveness in children ages 5-9 years exceeds 75%.
  • Immunity appears to persist ≥5 years after last vaccine dose in ~65% (empirical OR, 1.33; 95% CI, 1.23-1.43).
  • OR typically exceeds degree of waning effectiveness and correlates to ORs reported in literature (1.23-1.43).

Study design

  • Age-structured, population-based modeling study quantifying duration of DTaP immunity in 5 pediatric cohorts tracked from age 5 to 9 years across 8 years.
  • Funding: NIH.

Limitations

  • Nongeneralizable.
  • Limited sample.